8-K: IN8bio, Inc. Implements 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

IN8bio, Inc. has announced a 1-for-30 reverse stock split, effective June 5, 2025, to consolidate its common stock and adjust its share price.

Summary

• IN8bio, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-30 reverse stock split.
• The reverse stock split was authorized by the company's stockholders at their Annual Meeting held on May 8, 2025.
• The split will become effective at 5:00 p.m. Eastern Time on June 5, 2025.
• Trading on a split-adjusted basis will commence on The Nasdaq Capital Market when the market opens on June 6, 2025.
• The par value per share will remain unchanged at $0.0001.
• Outstanding stock options, warrants, and shares reserved under the 2023 Equity Incentive Plan and 2020 Employee Stock Purchase Plan will be proportionately adjusted.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment in lieu thereof.
• As of June 2, 2025, there were 103,327,028 shares of common stock outstanding, which will be reduced to approximately 3,444,234 shares immediately following the split.
• The new CUSIP number for the common stock following the reverse stock split will be 45674E208.

Sentiment

Score: 4

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for continued trading. However, it typically signals underlying challenges with the stock price and does not improve fundamental business performance, leading to a neutral to slightly negative overall sentiment.

Positives

• Helps the company meet or maintain Nasdaq listing requirements, potentially preventing delisting and ensuring continued market access.
• Simplifies the capital structure by reducing the total number of outstanding shares, which can make the stock appear more attractive to institutional investors.

Negatives

• A reverse stock split often indicates a low stock price, which can be perceived negatively by investors and may signal underlying financial or operational challenges.
• The action does not fundamentally change the company's valuation, business operations, or financial health.
• Can sometimes lead to further stock price decline post-split if underlying issues are not addressed or if market sentiment remains negative.

Risks

• The reverse stock split may not be sufficient to sustain the stock price above Nasdaq's minimum bid requirement in the long term.
• Potential for continued downward pressure on the stock price if market sentiment remains negative or if the company's operational performance does not improve.
• Risk of delisting if the stock price falls below the minimum bid requirement again after the split, despite the corporate action.

Future Outlook

The document primarily details the mechanics and effective dates of the reverse stock split. It does not provide explicit forward-looking statements regarding the company's financial performance, strategic direction, or operational guidance beyond the immediate impact of the share consolidation.

Management Comments

• The Board of Directors duly adopted a resolution proposing and declaring the advisability of this amendment to the Amended and Restated Certificate of Incorporation.
• The Certificate of Amendment was submitted to and duly adopted by the stockholders of the Corporation at an annual meeting, in accordance with Delaware law.

Industry Context

Reverse stock splits are a common corporate action, particularly for small-cap biotechnology companies like IN8bio, Inc., when their stock price falls below minimum exchange listing requirements (e.g., Nasdaq's $1.00 bid price). This action aims to increase the per-share price to maintain compliance and avoid delisting, which can severely impact liquidity and investor confidence. While it addresses a technical listing requirement, it does not inherently improve the company's underlying business fundamentals or financial health.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies, especially in the biotech sector, to regain compliance with stock exchange minimum bid price requirements, similar to actions taken by other small-cap biotechs facing delisting risks.
• The 1-for-30 ratio is a relatively aggressive split, indicating a significant need to boost the share price, which is not uncommon for companies whose stock has traded at very low levels for an extended period.
• The proportionate adjustment of options, warrants, and equity plans is standard industry practice to ensure fairness and prevent unintended dilution or enrichment of holders post-split.
• The provision for cash payment in lieu of fractional shares is also a common industry practice to simplify post-split shareholding and avoid issuing partial shares.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but each share will represent a proportionally larger ownership interest in the company. Those with fractional shares will receive cash. The primary impact is on the per-share price, potentially helping maintain liquidity and Nasdaq listing.
• Employees (with equity plans): Stock options and shares reserved under employee stock purchase plans will be adjusted proportionately, maintaining their intrinsic value and ownership percentage.

Next Steps

• Common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on June 6, 2025.
• Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof.

Key Dates

Recommendation

Keywords

IN8bio, INAB, Reverse Stock Split, Stock Consolidation, Nasdaq Listing, Biotechnology, SEC Filing, 8-K, Corporate Action, Share Capital Adjustment